FDMT 4D Molecular Therapeutics, Inc.

NEUTRAL Impact: 4/10 EFFECT
Horizon weeks Filed May 14, 2026 Processed 1mo ago SEC 9999999995-26-001626
IPO/offering going effective
Latest settled — T+5d
FDMT ▼ -11.42% at T+5d
NEUTRAL call ✗ call lost -11.42% · α vs SPY -10.70% · entry $9.81 → $8.69
Next anchor: T+20d due 24h ago
Currently $8.83 · -9.99% from $9.81 entry
Entry anchored
May 14, 2026
via day open
T+1d
-6.73%
call -6.73% · α -5.50%
$9.15
settled 29d ago
T+5d
-11.42%
call -11.42% · α -10.70%
$8.69
settled 23d ago
T+20d
call — · α —
due 24h ago
T+60d
call — · α —
in 8w

Price Chart

Loading chart...

Executive Summary

The SEC declared effective 4D Molecular Therapeutics' S-3 shelf registration (File No. 333-295650) on May 13, 2026, allowing the company to sell up to $400M in securities. The shelf replaces a prior expiring facility with $200M carried forward and $200M newly registered. With $458M cash on hand and runway into H2 2028, no immediate offering is expected, but the large size relative to the $546M market cap creates a persistent dilution overhang.

Actionable Insight

Monitor for any takedown announcement under the shelf, which would signal near-term dilution. The company's strong cash position suggests no urgency, but the shelf size relative to market cap means any offering could be meaningfully dilutive. Watch for clinical catalysts that could trigger capital needs.

Key Facts

  • Shelf registration (S-3) declared effective May 13, 2026
  • Total shelf size: $400M ($200M carried forward + $200M newly registered)
  • Company had $458M cash and runway into H2 2028 as of the prior S-3 filing
  • No concurrent offering announced; shelf provides flexibility for future capital raises

Financial Impact

Potential dilution of up to ~73% of current market cap ($400M shelf vs $546M market cap) if fully utilized

dilutionshare count

Risk Factors

  • Future offering under the shelf could dilute existing shareholders significantly
  • Large shelf relative to market cap may overhang the stock even without an offering
  • Clinical-stage biotech may need to access capital markets if pipeline milestones are delayed

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
82% bullish (17 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001626
Document: 9999999995-26-001626-index.html9999999995-26-001626
Document: 9999999995-26-001626.txt9999999995-26-001626
3 reports for FDMT
Performance horizon
Filters
Rows
Reports for FDMT — sortable, filterable
Type Now
May 14, 2026
4w ago
EFFECT
NEUTRAL ★ 4/10
$9.81 $8.69▼ −11.42%▼ −10.70%$8.83 (−9.99%)
May 7, 2026
5w ago
S-3
NEUTRAL ★ 4/10
$10.14 $9.81▼ −3.25%▼ −4.72%$8.83 (−12.92%)
Mar 18, 2026
12w ago
Press Release
NEUTRAL ★ 3/10
$8.98 $10.18▲ +13.36%▲ +15.57%$8.83 (−1.67%)
Showing 3 of 3

US Market Status

Market Closed — Opens Mon (49h 43m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access